Company / R&D per Share
Nuvalent, Inc. R&D per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$4.22
FY2025
5-year range
$1.28 / $4.22
FY2021-FY2025
Trend
+28.8%
vs FY2024
Sector context
#47 of 208
Health Care
What the data says
Nuvalent, Inc.'s r&d per share of $4.22 is higher than 77% of companies in the Health Care sector (FY2025). R&D per Share has increased for 3 consecutive years, from $1.28 in FY2022 to $4.22 in FY2025.
Based on SEC 10-K filings.
4.22 in FY2025 with a 5-year CAGR of -4.7%. Top quartile in the Health Care sector.
Improved from $1.94 to $4.22 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +48.8%
- 5-Year CAGR
- -4.7%
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 208This company $4.22 Sector average $28.82
▼
-85.3% below sector average
Key checks
Key Insights
- Nuvalent, Inc.'s r&d per share has grown for 3 consecutive years.
- In FY2025, r&d per share increased 28.8% year-over-year.
- Ranks #47 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.22 | +28.8% |
| FY2024 | $3.28 | +68.6% |
| FY2023 | $1.94 | +51.6% |
| FY2022 | $1.28 | -21.4% |
| FY2021 | $1.63 | -69.6% |
| FY2020 | $5.37 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026